Literature DB >> 12171295

Comparative reactivity of human sera to recombinant VlsE and other Borrelia burgdorferi antigens in class-specific enzyme-linked immunosorbent assays for Lyme borreliosis.

Louis A Magnarelli, Matthew Lawrenz1, Steven J Norris1, Erol Fikrig1.   

Abstract

A comparative study of human sera was conducted to determine which purified preparations of 11 recombinant antigens of Borrelia burgdorferi sensu stricto were diagnostically most important in enzyme-linked immunosorbent assays (ELISAs). To assess sensitivity, 20 serum samples obtained 1-6 weeks after onset of illness from 20 persons who had physician-diagnosed erythema migrans (EM) were tested for IgM and IgG antibodies. In tests for IgM antibody, seropositivity of > or = 25% was recorded when ELISAs had separate preparations of protein (p) 37, p41-G, outer-surface protein (Osp) C, OspE, OspF or VlsE antigens. Sera reacted most frequently (80% positive) with VlsE antigen in analyses for IgG antibodies. When results of both class-specific assays were considered for VlsE, OspC or OspF, 90% of the EM cases were serologically confirmed. Results of specificity testing with a further 59 sera from persons who had syphilis, louse-borne relapsing fever, oral infections, rheumatoid arthritis or human granulocytic ehrlichiosis and 28 normal sera indicated no false positive reactions when VlsE antigen was used in tests for IgM antibody. One of the 11 louse-borne relapsing fever sera cross-reacted with VlsE antigen in tests for IgG antibodies. Minor cross-reactivity also occurred when p37, OspC, OspE or OspF antigens were used. Overall, VlsE was the most suitable antigen for laboratory diagnosis of Lyme borreliosis during the early weeks of B. burgdorferi infection because of its high sensitivity and specificity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12171295     DOI: 10.1099/0022-1317-51-8-649

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  22 in total

1.  Serological confirmation of Borrelia burgdorferi infection in dogs in the Czech Republic.

Authors:  K Pejchalová; A Zákovská; K Fucík; P Schánilec
Journal:  Vet Res Commun       Date:  2006-04       Impact factor: 2.459

2.  Identification of Borrelia burgdorferi ribosomal protein L25 by the phage surface display method and evaluation of the protein's value for serodiagnosis.

Authors:  Markus Mueller; Sebastian Bunk; Isabel Diterich; Michael Weichel; Carolin Rauter; Dieter Hassler; Corinna Hermann; Reto Crameri; Thomas Hartung
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

3.  Evaluation of bioMérieux's Dissociated Vidas Lyme IgM II and IgG II as a First-Tier Diagnostic Assay for Lyme Disease.

Authors:  Claudia R Molins; Mark J Delorey; Adam Replogle; Christopher Sexton; Martin E Schriefer
Journal:  J Clin Microbiol       Date:  2017-03-22       Impact factor: 5.948

4.  Improvement of Lyme borreliosis serodiagnosis by a newly developed recombinant immunoglobulin G (IgG) and IgM line immunoblot assay and addition of VlsE and DbpA homologues.

Authors:  Gereon Goettner; Ulrike Schulte-Spechtel; Ruth Hillermann; Gabi Liegl; Bettina Wilske; Volker Fingerle
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

5.  Serum antibodies to whole-cell and recombinant antigens of Borrelia burgdorferi in cottontail rabbits.

Authors:  Louis A Magnarelli; Steven J Norris; Erol Fikrig
Journal:  J Wildl Dis       Date:  2012-01       Impact factor: 1.535

6.  Advances in Serodiagnostic Testing for Lyme Disease Are at Hand.

Authors:  John A Branda; Barbara A Body; Jeff Boyle; Bernard M Branson; Raymond J Dattwyler; Erol Fikrig; Noel J Gerald; Maria Gomes-Solecki; Martin Kintrup; Michel Ledizet; Andrew E Levin; Michael Lewinski; Lance A Liotta; Adriana Marques; Paul S Mead; Emmanuel F Mongodin; Segaran Pillai; Prasad Rao; William H Robinson; Kristian M Roth; Martin E Schriefer; Thomas Slezak; Jessica Snyder; Allen C Steere; Jan Witkowski; Susan J Wong; Steven E Schutzer
Journal:  Clin Infect Dis       Date:  2018-03-19       Impact factor: 9.079

7.  Epitope-Specific Evolution of Human B Cell Responses to Borrelia burgdorferi VlsE Protein from Early to Late Stages of Lyme Disease.

Authors:  Elzbieta Jacek; Kevin S Tang; Lars Komorowski; Mary Ajamian; Christian Probst; Brian Stevenson; Gary P Wormser; Adriana R Marques; Armin Alaedini
Journal:  J Immunol       Date:  2015-12-30       Impact factor: 5.422

8.  Effects of vlsE complementation on the infectivity of Borrelia burgdorferi lacking the linear plasmid lp28-1.

Authors:  Matthew B Lawrenz; R Mark Wooten; Steven J Norris
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

9.  Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease.

Authors:  Gary P Wormser; Martin Schriefer; Maria E Aguero-Rosenfeld; Andrew Levin; Allen C Steere; Robert B Nadelman; John Nowakowski; Adriana Marques; Barbara J B Johnson; J Stephen Dumler
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-11       Impact factor: 2.803

10.  Comparison of Western immunoblotting and the C6 Lyme antibody test for laboratory detection of Lyme disease.

Authors:  Elena Mogilyansky; Chien Chang Loa; Martin E Adelson; Eli Mordechai; Richard C Tilton
Journal:  Clin Diagn Lab Immunol       Date:  2004-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.